1-13 of 13
Bo Ahrén
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Reduction in Glycated Hemoglobin and Daily Insulin Dose Alongside Circadian Clock Upregulation in Patients With Type 2 Diabetes Consuming a Three-Meal Diet: A Randomized Clinical Trial

Daniela Jakubowicz, Zohar Landau, Shani Tsameret, Julio Wainstein, Itamar Raz, Bo Ahren, Nava Chapnik, Maayan Barnea, Tali Ganz, Miriam Menaged, Naomi Mor, Yosefa Bar-Dayan, Oren Froy
Journal: Diabetes Care
Diabetes Care 2019;42(12):2171–2180
https://doi.org/10.2337/dc19-1142
Published: 23 September 2019
View article titled, Reduction in Glycated Hemoglobin and Daily Insulin Dose Alongside Circadian Clock Upregulation in Patients With Type 2 Diabetes Consuming a Three-Meal Diet: A Randomized Clinical Trial
Open the PDF for Reduction in Glycated Hemoglobin and Daily Insulin Dose Alongside Circadian Clock Upregulation in Patients With Type 2 Diabetes Consuming a Three-Meal Diet: A Randomized Clinical Trial in another window
Includes: Supplementary data
Journal Articles

Influences of Breakfast on Clock Gene Expression and Postprandial Glycemia in Healthy Individuals and Individuals With Diabetes: A Randomized Clinical Trial

Daniela Jakubowicz, Julio Wainstein, Zohar Landau, Itamar Raz, Bo Ahren, Nava Chapnik, Tali Ganz, Miriam Menaged, Maayan Barnea, Yosefa Bar-Dayan, Oren Froy
Journal: Diabetes Care
Diabetes Care 2017;40(11):1573–1579
https://doi.org/10.2337/dc16-2753
Published: 22 August 2017
View article titled, Influences of Breakfast on Clock Gene Expression and Postprandial Glycemia in Healthy Individuals and Individuals With Diabetes: A Randomized Clinical Trial
Open the PDF for Influences of Breakfast on Clock Gene Expression and Postprandial Glycemia in Healthy Individuals and Individuals With Diabetes: A Randomized Clinical Trial in another window
Includes: Supplementary data
Journal Articles

Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial

Bo Ahrén, Irl B. Hirsch, Thomas R. Pieber, Chantal Mathieu, Fernando Gómez-Peralta, Troels Krarup Hansen, Areti Philotheou, Sune Birch, Erik Christiansen, Thomas Jon Jensen, John B. Buse, for the ADJUNCT TWO Investigators
Journal: Diabetes Care
Diabetes Care 2016;39(10):1693–1701
https://doi.org/10.2337/dc16-0690
Published: 04 August 2016
View article titled, Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial
Open the PDF for Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial in another window
Includes: Supplementary data
Journal Articles

Effect of the GLP-1 Receptor Agonist Lixisenatide on Counterregulatory Responses to Hypoglycemia in Subjects With Insulin-Treated Type 2 Diabetes

Johan Farngren, Margaretha Persson, Bo Ahrén
Journal: Diabetes Care
Diabetes Care 2016;39(2):242–249
https://doi.org/10.2337/dc15-1274
Published: 04 November 2015
View article titled, Effect of the GLP-1 Receptor Agonist Lixisenatide on Counterregulatory Responses to Hypoglycemia in Subjects With Insulin-Treated Type 2 Diabetes
Open the PDF for Effect of the GLP-1 Receptor Agonist Lixisenatide on Counterregulatory Responses to Hypoglycemia in Subjects With Insulin-Treated Type 2 Diabetes in another window
Journal Articles

Fasting Until Noon Triggers Increased Postprandial Hyperglycemia and Impaired Insulin Response After Lunch and Dinner in Individuals With Type 2 Diabetes: A Randomized Clinical Trial

Daniela Jakubowicz, Julio Wainstein, Bo Ahren, Zohar Landau, Yosefa Bar-Dayan, Oren Froy
Journal: Diabetes Care
Diabetes Care 2015;38(10):1820–1826
https://doi.org/10.2337/dc15-0761
Published: 28 July 2015
View article titled, Fasting Until Noon Triggers Increased Postprandial Hyperglycemia and Impaired Insulin Response After Lunch and Dinner in Individuals With Type 2 Diabetes: A Randomized Clinical Trial
Open the PDF for Fasting Until Noon Triggers Increased Postprandial Hyperglycemia and Impaired Insulin Response After Lunch and Dinner in Individuals With Type 2 Diabetes: A Randomized Clinical Trial in another window
Includes: Supplementary data
Journal Articles

HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin

Bo Ahrén, Susan L. Johnson, Murray Stewart, Deborah T. Cirkel, Fred Yang, Caroline Perry, Mark N. Feinglos
Journal: Diabetes Care
Diabetes Care 2014;37(8):2141–2148
https://doi.org/10.2337/dc14-0024
Published: 12 July 2014
View article titled, HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin
Open the PDF for HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin in another window
Includes: Supplementary data
Journal Articles

Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro

Julio Rosenstock, Vivian A. Fonseca, Jorge L. Gross, Robert E. Ratner, Bo Ahrén, Francis C.C. Chow, Fred Yang, Diane Miller, Susan L. Johnson, Murray W. Stewart, Lawrence A. Leiter
Journal: Diabetes Care
Diabetes Care 2014;37(8):2317–2325
https://doi.org/10.2337/dc14-0001
Published: 12 July 2014
View article titled, Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro
Open the PDF for Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro in another window
Includes: Supplementary data
Journal Articles

Efficacy and Safety of Lixisenatide Once-Daily Morning or Evening Injections in Type 2 Diabetes Inadequately Controlled on Metformin (GetGoal-M)

Bo Ahrén, MD, Aniceto Leguizamo Dimas, MD, Patrick Miossec, MD, Stéphane Saubadu, MD, Ronnie Aronson, MD
Journal: Diabetes Care
Diabetes Care 2013;36(9):2543–2550
https://doi.org/10.2337/dc12-2006
Published: 13 August 2013
View article titled, Efficacy and Safety of Lixisenatide Once-Daily Morning or Evening Injections in Type 2 Diabetes Inadequately Controlled on Metformin (GetGoal-M)
Open the PDF for Efficacy and Safety of Lixisenatide Once-Daily Morning or Evening Injections in Type 2 Diabetes Inadequately Controlled on Metformin (GetGoal-M) in another window
Includes: Supplementary data
Journal Articles

Changes in Prandial Glucagon Levels After a 2-Year Treatment With Vildagliptin or Glimepiride in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy

Bo Ahrén, MD, PHD, James E. Foley, PHD, Ele Ferrannini, MD, David R. Matthews, MD, Bernard Zinman, MD, Sylvie Dejager, MD, PHD, Vivian A. Fonseca, MD, FRCP
Journal: Diabetes Care
Diabetes Care 2010;33(4):730–732
https://doi.org/10.2337/dc09-1867
Published: 12 January 2010
View article titled, Changes in Prandial Glucagon Levels After a 2-Year Treatment With Vildagliptin or Glimepiride in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy
Open the PDF for Changes in Prandial Glucagon Levels After a 2-Year Treatment With Vildagliptin or Glimepiride in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy in another window
Journal Articles

Diabetes and Impaired Fasting Glycemia in a Rural Population of Bangladesh

M. Abu Sayeed, MD, PHD, Hajera Mahtab, FCPS, FRCP, Parvin Akter Khanam, MSC, Zafar Abdul Latif, FCPS, S. M. Keramat Ali, DPH, PHD, Akhter Banu, MSC, PHD, Bo Ahren, MD, PHD, A.K. Azad Khan, FCPS, PHD
Journal: Diabetes Care
Diabetes Care 2003;26(4):1034–1039
https://doi.org/10.2337/diacare.26.4.1034
Published: 01 April 2003
View article titled, Diabetes and Impaired Fasting Glycemia in a Rural Population of Bangladesh
Open the PDF for Diabetes and Impaired Fasting Glycemia in a Rural Population of Bangladesh in another window
Journal Articles

GLP-1 Tablet in Type 2 Diabetes in Fasting and Postprandial Conditions

Mark K Gutniak, MD, PHD, Hillevi Larsson, MD, Steven W Sanders, PHARMD, Olof Juneskans, PHD, Jens J Holst, MD, PHD, Bo Ahrén, MD, PHD
Journal: Diabetes Care
Diabetes Care 1997;20(12):1874–1879
https://doi.org/10.2337/diacare.20.12.1874
Published: 01 December 1997
View article titled, GLP-1 Tablet in Type 2 Diabetes in Fasting and Postprandial Conditions
Open the PDF for GLP-1 Tablet in Type 2 Diabetes in Fasting and Postprandial Conditions in another window
Journal Articles

Androgen Activity as a Risk Factor for Impaired Glucose Tolerance in Postmenopausal Women

Hillevi Larsson, MD, Bo Ahrén, MD, PHD
Journal: Diabetes Care
Diabetes Care 1996;19(12):1399–1403
https://doi.org/10.2337/diacare.19.12.1399
Published: 01 December 1996
View article titled, Androgen Activity as a Risk Factor for Impaired Glucose Tolerance in Postmenopausal Women
Open the PDF for Androgen Activity as a Risk Factor for Impaired Glucose Tolerance in Postmenopausal Women in another window
Journal Articles

Potential Therapeutic Levels of Glucagon-Like Peptide I Achieved in Humans by a Buccal Tablet

Mark K Gutniak, MD, PHD, Hillevi Larsson, MD, Sonia J Heiber, BSC, Olof T Juneskans, PHD, Jens J Holst, MD, PHD, Bo Ahrén, MD, PHD
Journal: Diabetes Care
Diabetes Care 1996;19(8):843–848
https://doi.org/10.2337/diacare.19.8.843
Published: 01 August 1996
View article titled, Potential Therapeutic Levels of Glucagon-Like Peptide I Achieved in Humans by a Buccal Tablet
Open the PDF for Potential Therapeutic Levels of Glucagon-Like Peptide I Achieved in Humans by a Buccal Tablet in another window